SCHEMBL4186462

SCHEMBL4186462

C[C@@H](CC1CCCCC1)NCc1ccccc1NS(N)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CTSD P07339 1/20 0.35
METAP2 P50579 4/20 0.34
METAP1 P53582 4/20 0.34
KMT2A Q03164 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MEN1 O00255 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33
F2RL1 P55085 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708795 0.88 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4202174 0.87 KDM4E (0.53) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4190409 0.86 POLB (0.44) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL12050344 0.86 KDM4E (0.55) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4194586 0.85 KDM4E (0.52) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4204377 0.85 KDM4E (0.43) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4184516 0.85 KDM4E (0.53) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4199567 0.83 KDM4E (0.52) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL4186532 0.83 KDM4E (0.44) KDM4EPKMLMNAPOLBALDH1A1
SCHEMBL23004843 0.83 METAP2 (0.37) POLBCTSDMETAP2METAP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 KDM4E 3328/4885PKM 1855/4885LMNA 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.